Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sitagliptin Shows No Increased Cardiovascular Risk In Merck’s TECOS Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Based on results of the TECOS study, Merck will seek approval to include additional safety information in the labeling for Januvia and Janumet.

You may also be interested in...



Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza

Merck got a complete response letter from FDA on a cardiovascular risk-reduction claim for the DPP-4 inhibitor based on TECOS trial data. This places Januvia/Janumet behind Jardiance, which already has a CV safety label claim, and Victoza, which awaits an FDA decision on a supplemental NDA filed last October.

Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response

The latest drug development news and highlights from our FDA Performance Tracker.

Diabetes Drug Safety Might Be Best Assessed With Real-World Data

Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078664

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel